Financial reports
10-K/A
2023 FY
Annual report (amended)
22 Mar 24
10-K
2023 FY
Annual report
14 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
10-K
2022 FY
Annual report
16 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
16 Mar 22
Current reports
8-K
Unregistered Sales of Equity Securities
18 Apr 24
8-K
Eton Pharmaceuticals Announces Acquisition of PKU GOLIKEĀ® for Phenylketonuria
22 Mar 24
8-K
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
14 Mar 24
8-K
Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation
21 Feb 24
8-K
Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules
2 Feb 24
8-K
Eton Pharmaceuticals Reports Third Quarter 2023 Financial Results
9 Nov 23
8-K
Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone
4 Oct 23
8-K
Eton Pharmaceuticals Reports Second Quarter 2023 Financial Results
10 Aug 23
8-K
Termination of a Material Definitive Agreement
5 Jul 23
8-K
Eton Pharmaceuticals Receives Complete Response Letter (CRL) for Dehydrated Alcohol Injection
28 Jun 23
Registration and prospectus
S-8
Registration of securities for employees
26 Mar 24
S-3
Shelf registration
7 Apr 23
S-8
Registration of securities for employees
20 Mar 23
424B3
Prospectus supplement
9 Apr 21
424B3
Prospectus supplement
7 Apr 21
424B5
Prospectus supplement for primary offering
15 Oct 20
424B5
Prospectus supplement for primary offering
13 Oct 20
S-3
Shelf registration
31 Jul 20
D
$7.5M in equity, sold $7.5M, 2 investors
8 Apr 20
424B5
Prospectus supplement for primary offering
30 Mar 20
Proxies
DEF 14A
Definitive proxy
26 Apr 24
DEF 14A
Definitive proxy
27 Apr 23
DEF 14A
Definitive proxy
28 Apr 22
DEF 14A
Definitive proxy
26 Apr 21
DEFA14A
Additional proxy soliciting materials
22 Apr 20
DEF 14A
Definitive proxy
22 Apr 20
DEFA14A
Additional proxy soliciting materials
26 Apr 19
DEF 14A
Definitive proxy
26 Apr 19
Other
EFFECT
Notice of effectiveness
3 May 23
CORRESP
Correspondence with SEC
1 May 23
UPLOAD
Letter from SEC
12 Apr 23
EFFECT
Notice of effectiveness
26 Aug 20
CORRESP
Correspondence with SEC
24 Aug 20
UPLOAD
Letter from SEC
4 Aug 20
UPLOAD
Letter from SEC
27 May 20
CORRESP
Correspondence with SEC
15 May 20
UPLOAD
Letter from SEC
5 May 20
EFFECT
Notice of effectiveness
17 Dec 19
Ownership